Effect of indomethacin on tumorigenicity and immunity induction in a murine model of mammary carcinoma

International Journal of Cancer

Volumn 75, Issue 6, 1998, Pages 894-899

  Morecki, S ^a   Yacovlev, L ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INDOMETACIN; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER IMMUNIZATION; CONTROLLED STUDY; DRUG EFFECT; IMMUNOSTIMULATION; INOCULATION; IRRADIATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR CELL; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; CYCLOOXYGENASE INHIBITORS; INDOMETHACIN; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; SURVIVAL ANALYSIS;

EID: 0031940250     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980316)75:6<894::AID-IJC12>3.0.CO;2-3     Document Type: Article

References (32)

1. AUNO, S.F., UNDA, F.J., IRUARRIZAGA, A., ALFARO, J., HILARIO, E., PEREZ YARZA, G., BOBADILLA, M. and LEJARRETA, M., Efficacy of liposome encapsulated indomethacin in response against metastasic 3LL and B16F1 tumor cells. Lab. Invest., 66, 671-679 (1992).
2. ANDREWS, J., HALLIDAY, G.M. and MULLER, H.K., A role for prostaglandins in the suppression of cutaneous cellular immunity and tumour development in benzo(a)pyrene but not dimethylbenz(a)anthracene treated mice. Clin. exp. Immunol., 85, 9-13 (1991).
3. CHAO, T.Y., TING, C.S., YEH, M. Y., CHANG, J. Y., WANG, C.C. and CHU, T.M., Effects of indomethacin on lymphokine activated killer cell activities in cancer patients. Tumor Biol., 16, 230-242 (1995).
4. COLOMBO, M.P. and FORNI, G., Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol. Today, 15, 48-51 (1994).
5. DEXTER, D.L., KOWALSKI, H.M., BLAZAR, B.A., FLIGIEL, Z., VOGEL, R. and HEPPNER, G., Heterogeneity of tumor cells from a single mouse mammary tumor. Cancer Res., 38, 3174-3181 (1978).
6. EARNEST, D.L., HIXSON, L.J. and ALBEST, D.S., Piroxan and other cyclooxygenase inhibitors: potential for cancer chemoprevention. J. cell. Biochem. (Suppl.). 161, 156-166 (1992).
7. FUJIWARA, H., MORIYAMA, Y., SUDA, T., TSUCHIDA, T., SHEARER, G.M. and HAMAOKA, T., Enhanced TNP reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression. J. Immunol., 132, 1571-1577 (1984).
8. FULTON, A.M., In vivo effects of indomethacin on the growth of murine mammary tumors. Cancer Res., 44, 2416-2420 (1984).
9. GOGOS, C.A., MAROULIS, J., ZOUMBOS, N.C., SALSA, B. and KALFARENTZOS, F., The effect of parenteral indomethacin on T lymphocyte subpopulations and cytokine in patients under major surgical operations. Res. exp. Med. (Berl.), 195, 85-92 (1995).
10. GOODWIN, J.S. and CEUPPENS, J., Regulation of the immune response by prostaglandins. J. clin. Immunol., 3, 295-315 (1983).
11. HAN, T., NEMOTO, T., LEDESMA, E.J. and BRUNO, S., Enhancement of T lymphocyte proliferate response to mitogens by indomethacin in breast cancer and colorectal cancer patients. Int. J. Immunopharmacol., 5, 11-15 (1983).
12. HOLMANG, S., CANO, M., GRENABO, L., HEDELIN, H. and JOHANSSON, S.L., Effect of indomethacin on N-[4-(5-nitro-2-furyl)-2-thiazolyl]tormamide induced urinary carcinogenesis. Carcinogenesis, 16, 1493-1498 (1995).
13. JIMBO, T., AKIMOTO, T. and TOHGO, A., Effect of combined administration of a synthetic low toxicity lipid A derivative, DT5461a, and indomethacin in various experimental tumor models of colon 26 carcinoma in mice. Cancer Immunol. Immunotner., 40, 10-16 (1995).
14. KAPLAN, E. and MEIER, P., Non-parametric estimation from incomplete observation. J. Amer. Statist. Ass., 53, 457-181 (1958).
15. KHAN, M.M., SANSONI, P., ENGLEMAN, E.G. and MELOM, K.L., Pharmacologic effects of autacoids on subsets of T cells. J. clin. Invest., 75, 1578-1583 (1985).
16. LALA, P.K., PARHAR, R. and SINGH, P., Indomethacin therapy abrogates the prostaglandin mediated suppression of natural killer activity in tumor bearing mice and prevents tumor metastasis. Cell. Immunol., 99, 108-118 (1986).
17. LALA, P.K., PARHAR, R.S., SINGH, P. and LALA, P.K., Cure of murine Ehrlich ascites tumors with chronic oral indomethacin therapy combined with intraperitoneal administration of LAK cells and IL-2. Cancer Lett., 51, 27-35 (1990).
18. LALA, P.L. and PARHAR, R.S., Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ. Cancer Res., 48, 1072-1079 (1988).
19. LALA, P.L. and PARHAR, R.S., Eradication of spontaneous and experimental adenocarcinoma metastases with chronic indomethacin and intermittent IL-2 therapy. Int. J. Cancer, 54, 677-684 (1993).
20. LIU, C.M., OKAYASU, T., GOLDMAN, P., SUZUKI, Y., SUZUKI, K. and WEELOCK, E.F., Immune regulation of the L5178Y murine tumor dormant state. I. In vivo and in vitro effects of prostaglandin E2 and indomethacin on tumor cell growth. J. exp. Med., 164, 1259-1273 (1986).
21. MANTEL, N., Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 50, 163-170 (1966).
22. MORECKI, S., MOSHEL, Y., GELFEND, Y., PUGATSCH, T. and SLAVIN, S., Induction of graft vs. tumor effect in a murine model of mammary adenocarcinoma. Int. J. Cancer, 71, 59-63 (1997).
23. PARHAR, R.S. and LALA, P.K., Changes in the host natural killer cell population in mice during tumor development. 2. The mechanism of suppression of NK activity. Cell. Immunol., 93, 265-279 (1985).
24. PETERSON, M., YOSHIZUMI, M.O., HELPER, R., MONDINO, B. and KREIGER, A., Topical indomethacin in the treatment of chronic cystoid macular edema. Graefes Arch. clin. exp. Ophthalmol., 230, 401-405 (1992).
25. PLANCHON, P., VEBER, N., MAGNIEN, V., PREVOST, G., STARZEC, A.B. and ISRAKL, L., Evidence for separate mechanisms of antiproliferative action of indomethacin and prostaglandin on MCF-7 breast cancer cells. Life Sci., 57, 1233-1240 (1995).
26. 2 inhibits the production of human interleukin-2. J. exp. Med., 155, 943-948 (1982).
27. ROSENBERG, S.A. and 12 OTHERS, A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high dose interleukin-2 alone. N. Engl. J. Med., 316, 889-897 (1987).
28. 2 mediated suppression. Surgery, 92, 528-532 (1982).
29. 2 formation and histamine action in cancer immunotherapy. Cancer Immunol. Immunother., 37, 251-254 (1993).
30. VON HOEGEN, P., HEICAPELL, R., GRIESBACH, A., ALTEVOGT, P. and SCHIRRMACHER, V., Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. III. Postoperative activation of tumor specific CTLP from mice with metastases requires stimulation with specific antigen plus additional signals. Invasion Metastasis. 9, 117-133 (1989).
31. WEST, W.H., TAUER, K.W., YANELLI, J.R., MARSHALL, G.D., ORR, D.W., THURMAN, G.B. and OLDHAM, R.K., Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advance cancer. N. Engl. J. Med., 316, 898-905 (1987).
32. WILD, D. and DEGAN, G.H., Prostaglandin H synthetase dependent mutagenic activity of heterocyclic aromatic amines of the IQ type. Carcinogenesis, 8, 541-545 (1987).